AzurBio

Empowering biopharmaceutical companies with a 1st life-changing medicine to expand to Europe.

 

Contact us

Europe. A fantastic opportunity for biopharmaceutical companies.

Illustration home 1-1

EU is the

2nd*

largest market globally

for prescription medicines

*23% Europe - Deloitte, 2024

Europe. A challenging and complex market to address.

Group 370

Europe is Not a country

  • Multiple regulatory and market access environments vs the US
  • Market differences between individual European countries
Group 371

Need Expertise and focused efforts to

  • Understand Europe as a whole & as individual markets
  • Adopting a strategic approach to market prioritization

Our Solutions.

We provide innovative solutions to enter the EU market by maximizing flexibility and minimizing operational burden, from registration through to commercialization. 

ILLUSTRATION 4_13@2x

Expand to Europe

A unique partnership model that goes beyond traditional full outsourcing or licensing agreements.

ILLUSTRATION 4_14@2x
flag-france

Unlock France

Meeting France's Exploitant requirements efficiently & compliantly.

ILLUSTRATION 4_7@2x
flag-europe

Consulting

Strategic guidance, tailored solutions, and regulatory services for life sciences products (pharmaceuticals, medical devices & others) — from early development to market launch and beyond.

Our Clients. Innovators in rare or serious diseases.

Group 372@3x
Home illustration 7

Our Mission in motion.

Azurbio
Azurbio

AzurBio. The partner of choice for biopharmas.

tour-effel
  • Paris (Headquarter)
  • Nice
  • Zug
statue-liberte
  • Boston
  • New York
Illustration-1

Our Strategic Committee. Seasoned Industry Experts.

team-5
Corinne Schmitz
Chairman, Founder & CEO at AzurBio
team-2
Antoine Barouky
Former VP General Manager EU at Alnylam
team-3
Marc Lefrançois
Health Industry Partner at CMI
team-1
Stéphane André
Former SVP Head of Global Regulatory Affairs at Ipsen

Our Affiliations.

EUCOPE
MABDESIGN
LEEM
RAPS

Looking to enter the EU market?
Contact us today.